Finally, VIP is used as a potent vasorelaxant drug clinically, so it will be interesting to test whether treatment with VIP or other VIPR1 agonists will generate beneficial effects for the treatment of HCC. Here, VIPR1 is linked to hepatocellular carcinoma.